Trial Profile
A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OPAL
- Sponsors GlaxoSmithKline; GSK; TESARO
- 14 Feb 2023 The trial has been discontinued in Denmark, according to European Clinical Trials Database record.
- 19 Apr 2022 Planned End Date changed from 9 Mar 2026 to 31 Mar 2026.
- 19 Apr 2022 Planned primary completion date changed from 16 Jul 2024 to 6 Aug 2024.